CorMedix Inc. focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings.
